ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American Association for Cancer Research (AACR) Annual Meeting 2023
/PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for...
United States Orange County Convention Center United Kingdom Tom Mccarthy James Westcott Prnewswire Thirtyfivebio
Source: prnewswire.com